Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | HCAR3 | P49019 | 10/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11707399 | 0.88 | KMT2A (0.62) | KMT2AMAPTNPSR1HTTHCAR3 | |
| SCHEMBL29793669 | 0.88 | KMT2A (0.68) | KMT2AMAPTNPSR1HTTHCAR3 | |
| SCHEMBL2643864 | 0.88 | KMT2A (0.68) | KMT2AMAPTNPSR1HTTHCAR3 | |
| SCHEMBL3613079 | 0.86 | HCAR3 (0.72) | KMT2AMAPTNPSR1HCAR3MEN1 | |
| SCHEMBL506550 | 0.84 | HCAR3 (0.74) | KMT2AMAPTHTTHCAR3ALDH1A1 | |
| SCHEMBL571622 | 0.84 | KMT2A (0.64) | KMT2AMAPTNPSR1HTTHCAR3 | |
| SCHEMBL9137225 | 0.84 | KMT2A (0.76) | KMT2AMAPTNPSR1HTTHCAR3 | |
| Hydrochloric Acid SCHEMBL18813442 | 0.83 | HCAR3 (0.72) | KMT2AMAPTHTTHCAR3ALDH1A1 | |
| SCHEMBL28435038 | 0.83 | KMT2A (0.60) | KMT2AMAPTNPSR1HTTHCAR3 | |
| SCHEMBL10102440 | 0.83 | KMT2A (0.60) | KMT2AMAPTNPSR1HTTHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9468694-B2 | Fluorination process | GE HEALTHCARE LIMITED (GB) | 2016-10-18 | — | — | US | disclosed |
| US-9468694-B2 | Fluorination process | GE HEALTHCARE LIMITED (GB) | 2016-10-18 | — | — | US | disclosed |
| US-9468694-B2 | Fluorination process | GE HEALTHCARE LIMITED (GB) | 2016-10-18 | — | — | US | disclosed |
| US-20150328344-A1 | Fluorination Process | GE HEALTHCARE AS (NO) | 2015-11-19 | — | — | US | disclosed |
| US-20150328344-A1 | Fluorination Process | GE HEALTHCARE AS (NO) | 2015-11-19 | — | — | US | disclosed |
| US-20150328344-A1 | Fluorination Process | GE HEALTHCARE AS (NO) | 2015-11-19 | — | — | US | disclosed |
| CN-102731432-B | The fluorination process of anilid derivative and the benzothiazole fluorinated derivatives as in-vivo imaging agent | GE HEALTHCARE LTD. (GB) | 2015-10-21 | — | — | CN | disclosed |
| US-9126961-B2 | Fluorination process | GE HEALTHCARE LIMITED (GB) | 2015-09-08 | — | — | US | disclosed |
| US-9126961-B2 | Fluorination process | GE HEALTHCARE LIMITED (GB) | 2015-09-08 | — | — | US | disclosed |
| US-9126961-B2 | Fluorination process | GE HEALTHCARE LIMITED (GB) | 2015-09-08 | — | — | US | disclosed |
| US-20100234611-A1 | Fluorination Process of Anilide Derivatives and Benzothiazole Fluorinate Derivatives as in VIVO Imaging Agents | GE HEALTHCARE LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| CN-101282920-A | Method for fluorination of anilide derivatives and benzothiazole fluorinated derivatives as in vivo imaging agents | GE HEALTHCARE LTD (GB) | 2008-10-08 | — | — | CN | disclosed |
| EP-1915330-A1 | FLUORINATION PROCESS OF ANILIDE DERIVATIVES AND BENZOTHIAZOLE FLUORINATE DERIVATIVES AS IN VIVO IMAGING AGENTS | GE Healthcare Limited (GB) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007020400-A1 | FLUORINATION PROCESS OF ANILIDE DERIVATIVES AND BENZOTHIAZOLE FLUORINATE DERIVATIVES AS IN VIVO IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2007-02-22 | — | — | WO | disclosed |
| US-5514676-A | TO INHIBIT THE FORMATION OF ADVANCED GLYCOSLYATION PRODUCTS BY THE NONENZYMATIC CROSSLINKING OF PROTEINS WITH REDUCING SUGARS, USED IN FOOD PRESERVATION AND TO PREVENT PROTEIN AGING IN COLLAGEN OR LENSES IN THE EYE PRESERVATION | THE ROCKEFELLER UNIVERSITY (US) | 1996-05-07 | — | — | US | disclosed |
| US-5476849-A | Inhibiting advanced glycosylation and/or crosslinking of target protein | THE ROCKEFELLER UNIVERSITY (US) | 1995-12-19 | — | — | US | disclosed |
| US-4312873-A | FUNGICIDES | SYNTEX (U.S.A.) INC. (US) | 1982-01-26 | — | — | US | disclosed |
| US-4191764-A | FUNGICIDES | SYNTEX (U.S.A.) INC. (US) | 1980-03-04 | — | — | US | disclosed |
| US-4139626-A | FUNGICIDES | SYNTEX (U.S.A.) INC. (US) | 1979-02-13 | — | — | US | disclosed |
| US-4086235-A | PESTICIDES, ANTHELMINTICS, ANTIFUNGAL AGENTS | SYNTEX (U.S.A.) INC. (US) | 1978-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328344-A1 | Fluorination Process | CYP2F1, C1R, C1S | KMT2A 1861/4885MAPT 4584/4885NPSR1 992/4885 |
| US-20100234611-A1 | Fluorination Process of Anilide Derivatives and Benzothiazole Fluorinate Derivatives as in VIVO Imaging Agents | Q6ZSR9, AFF1, F9 | KMT2A 1522/4885MAPT 3510/4885NPSR1 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.